Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects

Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2015, Pages 688-697

  Scherz, Michael W ^a   Brossard, Patrick ^a   D'Ambrosio, Daniele ^a   Ipek, Murat ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

desensitization; healthy subjects; ponesimod; S1P1 receptor modulator; up titration regimen

Indexed keywords

PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR EFFECT; CROSSOVER PROCEDURE; DESENSITIZATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; LYMPHOCYTE COUNT; MAINTENANCE DRUG DOSE; MALE; MORNING DOSAGE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PR INTERVAL; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; LYMPHOCYTE; MIDDLE AGED; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RECEPTORS, LYSOSPHINGOLIPID; THIAZOLES; YOUNG ADULT;

EID: 84928882807     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.467     Document Type: Article

References (14)

1. 1 receptor modulators. J Med Chem. 2010; 53: 4198-4211.
2. Thangada S, Khanna KM, Blaho VA, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med. 2010; 207: 1475-1483.
3. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 modulator ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011; 337: 547-556.
4. 1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013; 76: 888-896.
5. 1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol. 2014; 54: 179-188.
6. Legangneux E, Gardin A, Johns D,. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013; 75: 831-841.
7. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012; 167: 1035-1047.
8. 1 receptor modulator. PLoS. 2013; 8: e74285.
9. Chun J, Brinkmann V,. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011; 12: 213-228.
10. Song J, Matsuda C, Kai Y, et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther. 2008; 324: 276-283.
11. Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014; 384: 2036-2045.
12. Olsson T, Boster A, Fernandez O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014; 85: 1198-1208.
13. Atkinson KE,. The trapezoidal rule and Simpson's rule. An Introduction to Numerical Analysis. 2nd ed. New York: John Wiley & Sons; 1989.
14. Nakagawa M, Oda M, Iwao T, et al. Signal-averaged electrocardiogram shows a heart rate dependent diurnal variation in healthy subjects. Jpn Heart J. 1998; 39: 147-152.